ReviewClinical hypertension2023
The 2022 focused update of the 2018 Korean Hypertension Society Guidelines for the management of hypertension.
Review in Clinical hypertension, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
101 citing papers in PubMed, 4 syntheses or guidelines pooled it, 138 citations in OpenAlex.
- Associations Between Polygenic Risk Score for Blood Pressure and Risk of Hypertension in Northeast Asian Individuals.Journal of the American Heart Association · 2026Pooled it
- Current guidelines in hypertension management with special focus on management of extremely high blood pressure: a systematic review.BMC cardiovascular disorders · 2025Pooled it
- Safety classification of herbal medicine use among hypertensive patients: a systematic review and meta-analysis.Frontiers in pharmacology · 2024Pooled it
- 2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association.Diabetes & metabolism journal · 2023Guideline
- Comparison of the effects of inspiratory muscle strength training and aerobic exercise training on vascular function in patients with hypertension.European journal of applied physiology · 2026Trial
- Trial
- Low-Dose TEL/AML/CHTD SPC Versus Standard-Dose TEL in Hypertension: Phase III RCT.Hypertension (Dallas, Tex. : 1979) · 2026Trial
- Effectiveness of a Personalized Digital Exercise and Nutrition Rehabilitation Program in Postoperative Patients With Gastric Cancer: Randomized Controlled Trial.JMIR mHealth and uHealth · 2026Trial
- Efficacy and Safety of Telmisartan 20 mg/S-Amlodipine 2.5 mg versus Telmisartan 40 mg in Patients with Hypertension, Inadequately Controlled on Telmisartan 20 mg Monotherapy: A Randomized, Double-Blind, Multicenter, Phase 3 Trial.Drug design, development and therapy · 2026Trial
- Efficacy of Olmesartan/Amlodipine Single-Pill Combination on 24-h Mean Systolic Blood Pressure Measured by Ambulatory Monitoring in Non-Responders to Valsartan or Candesartan Monotherapy.Journal of clinical hypertension (Greenwich, Conn.) · 2025Trial
- A novel clinical biomarker-based Physiology Healthy Aging Index and risk of all-cause and cause-specific mortality: A 20-year prospective cohort study.GeroScience · 2026Article
- Muscle Strength Profiles According to Kidney Dysfunction and Anemia Status in Korean Adults Aged ≥40 Years: A Nationwide Cross-Sectional Study.Healthcare (Basel, Switzerland) · 2026Article
- Age-stratified association between blood pressure and clinical outcomes in maintenance hemodialysis patients.International urology and nephrology · 2026Article
- Single-Pill Combination Olmesartan/Amlodipine/Hydrochlorothiazide Safety and Effectiveness in Older Patients with Hypertension: Pooled Analysis of Post-Approval Observational Studies.Advances in therapy · 2026Article
- Integrating Blood Pressure Control With Multi-Class Kidney Protective Agents in Diabetic Kidney Disease.Electrolyte & blood pressure : E & BP · 2026Review
- Reassessing home blood pressure thresholds: clinical implications of lowering the diagnostic criteria to 130/80 mmHg.Journal of hypertension · 2026Article
- Combination of Fimasartan and Statins in Patients With Hypertension and Dyslipidemia.Journal of lipid and atherosclerosis · 2026Article
- 2025 Obesity Fact Sheet for Korea: Prevalence of Obesity, Abdominal Obesity from 2014 to 2023 and Prevalence of Chronic Disease by Obesity Status.Journal of obesity & metabolic syndrome · 2026Article
- Clinical impact of proteinuria and blood pressure variability on long-term outcomes after percutaneous coronary intervention.Scientific reports · 2026Observational
- Preference, Awareness, and Use of Sphygmomanometers in the Mercury-Free Era: A Cross-Sectional Survey of Physicians in Korea.Journal of Korean medical science · 2026Article
41 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension is the leading cause of death in human being, which shows high prevalence and associated complications that increase the mortality and morbidity. Controlling blood pressure (BP) is very important because it is well known that lowering high BP effectively improves patients' prognosis. This review aims to provide a focused update of the 2018 Korean Hypertension Society Guidelines for the management of hypertension. The importance of ambulatory BP and home BP monitoring was further emphasized not only for the diagnosis but also for treatment target. By adopting corresponding BPs, the updated guideline recommended out-of-office BP targets for both standard and intensive treatment. Based on the consensus on corresponding BPs and Systolic Blood Pressure Intervention Trial (SPRINT) revisit, the updated guidelines recommended target BP in high-risk patients below 130/80 mmHg and it applies to hypertensive patients with three or more additional cardiovascular risk factors, one or more risk factors with diabetes, or hypertensive patients with subclinical organ damages, coronary or vascular diseases, heart failure, chronic kidney disease with proteinuria, and cerebral lacunar infarction. Cerebral infarction and chronic kidney disease are also high-risk factors for cardiovascular disease. However, due to lack of evidence, the target BP was generally determined at < 140/90 mmHg in patients with those conditions as well as in the elderly. Updated contents regarding the management of hypertension in special situations are also discussed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.